Abstract: It is an object of the present invention to generate stable plasma and carry out continuous discharge while at the same time preventing the adherence of dust to a mouth side electrode by arranging the mouth side electrode outside the container to face a container side electrode.

Abstract: It is an object of the present invention to provide a container in which it is difficult for liquid to drip at a mouth portion having a good touch sensation by forming a structure in which a welded portion that was laser welded in a sealed container does not form a flange, and to carry out the achievement of making polymer material unnecessary and making excessive material in the seaming portion unnecessary. Further, it is also an object to construct the lid and barrel of the vessel by using the same material, thereby facilitating the recycling of material.

Abstract: A method and apparatus for cleaning a source gas introduction pipe, which can prevent strong adhesion of contaminant mainly containing carbon powder on an outer surface of the source gas introduction pipe to easily remove the contaminant in a short period of time. While compressed air is sprayed toward the contaminant, the contaminant removed by the spray of the compressed air is exhausted outside a system of a deposition chamber by suction and exhausting device so that the contaminant is not transferred to sides of the deposition chamber and a plastic container in which a CVD film is formed, in a process for extracting the source gas introduction pipe from the plastic container after the CVD film is formed on an inner surface of the plastic container.

Abstract: Disclosed is an apparatus for producing DLC film-coated plastic containers, which comprises an outer electrode unit disposed outside a plastic container, an inner electrode disposed inside the plastic container, a duct through which a raw material gas of a carbon source is fed into the plastic container having been degassed, and a high-frequency oscillator for applying a voltage between the outer electrode unit and the inner electrode with a carbon source gas being fed into the container, thereby to generate plasma to form a DLC film on the inner surface of the plastic container. In the apparatus, the outer electrode unit comprises a bottom electrode disposed along the bottom of the plastic container, and a body electrode disposed along the body of the plastic container, and the upper edge of the bottom electrode is positioned below the center between the top and the bottom of the plastic container.

Abstract: A method of manufacturing a gas barrier film coated plastic container with high gas-barrier properties by solving a problem in a conventional method wherein the formation of a gas barrier film is obstructed by water molecules adsorbed in the plastic container and the container with reduced gas-barrier properties is manufactured. The method is characterized by comprising the steps of decreasing a pressure inside the plastic container or decreasing a pressure to the entire part of the plastic container, flowing dry gas as leak gas when vacuum is released to fill the inside of the container with the dry gas for drying the plastic container, replacing the gas inside the plastic container with a material gas or a material gas-containing gas, and plasmatizing the material gas to form the gas barrier film on the inner surface of the plastic container by a CVD method.

Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

Abstract: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(?-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.

Abstract: The present invention provides a plastic container having a inner wall surface coated with DLC film which has same level of oxygen barrier property as prior art and can prevent a coloring of the DLC film formed on a neck portion of the container, manufacturing apparatus therefor and manufacturign method thereof.

Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

Abstract: The present invention relates to pharmaceutical composition comprising SCF protein, IL-3 protein, GM-CSF protein and IL-6 protein. More specifically, the present invention relates to a protecting agent from radiation hazards, comprising SCF protein, IL-3 protein, GM-CSF protein and IL-6 protein.The present invention also relates to a method for the treatment of patients with radiation hazards, which comprises administering the pharmaceutical composition according in a therapeutically effective amount to the patients.The present invention has an excellent effect of enabling 100% survival of animals exposed to a lethal dose of radiations, which could not be attained by prior art pharmaceuticals.

Abstract: Microorganism cells such as Saccharomyces or Candida yeast cells are treated with an alkaline aqueous solution with heating and stirring or with a cell wall dissolving enzyme such as glucanase or mannase to obtain cells that function as microcapsules by rapidly taking up a large amount of hydrophobic liquid. Treatment with an alkaline aqueous solution is preferably carried out at a pH of at least 8 for at least 1 hour at a temperature of 20.degree.-100.degree. C. A preferred embodiment of enzyme treatment is with .beta.-1,3-glucanase for about 30 minutes to 5 hours at pH 4-9 at a temperature of 30.degree.-60.degree. C. The treatments dissolve cell walls of the yeast such that the walls still have sufficient strength for enclosing hydrophobic liquids.

Abstract: There is provided by this invention a finely divided hydrated silica gel which has a specific surface area of 530 -720 m.sup.2 /g, preferably 550-650 m.sup.2 /g, a pore volume of 0.9-1.5 ml/g, preferably 1.0-1.4 ml/g, a mean pore diameter of 50-120 .ANG., preferably 60-100 .ANG., a water content of 7-25% by weight, preferably 8-13% by weight (wet weight basis), and moreover the pH of which as a 5% aqueous suspension is 6.0-8.0, thereby producing a silica gel suitable for stabilization treatment of beer, and for reduction of the colloidal components in beer.

Abstract: There is provided by this invention a finely divided hydrated silica gel which has a specific surface area of 530-720 m.sup.2 /g, preferably 550-650 m.sup.2 g, a pore volume of 0.9-1.5 ml/g, preferably 1.0-1.4 ml/g, a mean pore diameter of 50-120 .ANG., preferably 60-100 .ANG., a water content of 7-25% by weight, preferably 8-13% by weight (wet weight basis), and moreover the pH of which as a 5% aqueous suspension is 6.0-8.0, thereby producing a silica gel suitable for stabilization treatment of beer, and for reduction of the colloidal components in beer.

Abstract: KS-2-B was obtained as purified material from the culture of Daedalea dickinsii KSDD 6 (FERM-P No. 3993), Lentinus edodes KSLE 7 (FERM-P No. 3994) or Lentinus edodes KSLE 28 (FERM-P No. 4196). This substance, KS-2-B, is an effective interferon inducing substance.